MediciNova, Inc.
- MNOV
- NASDAQ
- Biotechnology
- CNS/Inflammation Drug (ibudilast)
$1.40
Today −1.41%Quote Oct 19, 2026, 08:00 PM UTC
−57.83%over the last month
Max drawdown −57.8%From 1-month high −57.8%3 months +5.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About MediciNova
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
6
Market value
$68.9M
Quote Oct 19
Analyst target
$6.00
+328.6% from here
Floor
$1.38
1.6% below price
Resistance
$1.41
0.5% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about MNOVPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free